Identification of atrial fibrillation patients who are at high bleeding risk after undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial

28 August 2018 (10:05 - 10:55)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Tarek Nafee

Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail

NOACs versus warfarin in atrial fibrillation patients and risk of dementia: a nationwide propensity-weighted cohort study

Mrs M. Soegaard (Aalborg, DK)

Abstract Slides

Presentation thumbnail

Resuming anticoagulation in patients with atrial fibrillation experiencing hemorrhage stroke or nontraumatic intracranial hemorrhage

Assistant Professor V. Wu (Tao-Yuan, TW)

Abstract Slides

Presentation thumbnail

Geographic region, stroke risk and renal function strongly affect treatment choice for stroke prevention in patients with non-valvular AF: results from the GLORIA-AF registry program

Doctor L. Riou Franca (Ingelheim, DE)

Presentation thumbnail

Thrombosis of left atrial appendage closure devices - What is the clinical impact?

Doctor V. Lekesova (Prague, CZ)

Abstract Slides

Presentation thumbnail

Effect of anticoagulation on mortality by CHADSVASC score in patients with atrial fibrillation: comparison to patients without atrial fibrillation

Doctor S. Harb (Cleveland, US)

Abstract Slides

Access the full session

Session thumbnail

Atrial fibrillation - Anticoagulation

The Event

ESC Congress 2018

28 August 2018 10:05 CET

You may be interested in

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Presentation

State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope

Congress Session

Oral anticoagulation in subclinical atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources